Vertex Pharmaceuticals Incorporated
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: TEZ/IVADrug: VX-445/TEZ/IVADrug: IVADrug: Placebo
- First Posted Date
- 2018-05-15
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 113
- Registration Number
- NCT03525548
- Locations
- πΊπΈ
Banner University of Arizona Medical Center, Tucson, Arizona, United States
πΊπΈUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
πΊπΈMiller Children's Hospital/ Long Beach Memorial, Long Beach, California, United States
A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
- First Posted Date
- 2018-05-15
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 507
- Registration Number
- NCT03525574
- Locations
- πΊπΈ
Banner University of Arizona Medical Center, Tucson, Arizona, United States
πΊπΈUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
πΊπΈMiller Children's Hospital / Long Beach Memorial, Long Beach, California, United States
A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: PlaceboDrug: VX-445/TEZ/IVADrug: IVA
- First Posted Date
- 2018-05-15
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 405
- Registration Number
- NCT03525444
- Locations
- πΊπΈ
Banner University of Arizona Medical Center, Tucson, Arizona, United States
πΊπΈUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
πΊπΈMiller Children's Hospital/ Long Beach Memorial, Long Beach, California, United States
A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 16
- Registration Number
- NCT03486236
- Locations
- π¬π§
The Medicines Evaluation Unit, Manchester, United Kingdom
A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2019-10-17
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 116
- Registration Number
- NCT03460990
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈYale New Haven Medical Center, New Haven, Connecticut, United States
πΊπΈUniversity of Miami/Miller School of Medicine, Miami, Florida, United States
A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 385
- Registration Number
- NCT03447249
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈStanford University, Palo Alto, California, United States
πΊπΈChildren's Hospital Colorado, Aurora, Colorado, United States
A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 484
- Registration Number
- NCT03447262
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈStanford University, Palo Alto, California, United States
πΊπΈChildren's Hospital Colorado, Aurora, Colorado, United States
A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy
- First Posted Date
- 2017-10-09
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 89
- Registration Number
- NCT03304522
- Locations
- πΊπΈ
Xenoscience Inc. - 21st Century Neurology, Phoenix, Arizona, United States
πΊπΈPhoenix Neurological Associates, Ltd., Phoenix, Arizona, United States
πΊπΈSutter Health - Alta Bates Summit Medical Center - The Jordan Research & Education Institute, Berkeley, California, United States
Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Registration Number
- NCT03278314
A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: IVA
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 86
- Registration Number
- NCT03277196
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈStanford University, Palo Alto, California, United States
πΊπΈAlfred I DuPont Hospital for Children, Wilmington, Delaware, United States